All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

/images/Cortellis_Flagship_Logo_TM_RGB_Color.png
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Artificial intelligence
    • Coronavirus
    • Diagnosing and tracking COVID-19
    • Drugs to Watch 2020
    • The next pandemic
    • Premium reports
      • BioWorld Financings Reports
      • Disease Forecast Reports

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Wednesday, March 3, 2021
Home » Blogs » BioWorld MedTech Perspectives » FDA whistleblowers sue FDA: A big deal?

BioWorld MedTech Perspectives
BioWorld MedTech Perspectives RSS FeedRSS

BioWorld MedTech / CDRH

FDA whistleblowers sue FDA: A big deal?

Feb. 1, 2012
By Mark McCarty
No Comments

Seriously, what's the big deal?

Fans of pro football may think the matter of whether Peyton Manning will ever play in the NFL again is taking forever to come to a conclusion, but they might want to examine the FDA whistleblower issue as a benchmark for drawn-out drama.

As has been reported in Medical Device Daily, former FDA employees, including Robert C. Smith, MD, and Julian Nicholas, MD, were among the authors of letters to Congress and the Obama administration over alleged suppression of dissent over medical device approvals. Those letters came out in 2008 and 2009, and the story of a new lawsuit by some of the authors of those letters against FDA is all over the Internet. The lawsuit alleges that FDA's practice of monitoring e-mail communication on agency computers violated the privacy rights of the senders.

Smith is quoted in the Washington Post piece as saying (apparently in outrage): “Who would have thought they would have the nerve to be monitoring my communications to Congress?” He is said to have inquired further: “How dare they?”

Well, it seems FDA dares. The reader will pardon me for editorializing, but if your employer tells you up front that your computer activity may be monitored, you probably ought not use those computers to send out things that could get you in trouble.

As the saying goes, “duh.”

So what gives with the kindly Dr. Smith & Co.? Tough to say, but Smith had filed a whistleblower lawsuit against Yale New Haven Hospital (YNHH; New Haven, Connecticut) and several other hospitals that was dismissed in 2006. A few items in that decision are of special interest in this discussion, including that “the United States declined to intervene in the action.”

The decision states that Smith's allegation that the hospital's use of an autosign program disallows billing for the technical component of a radiological study ignores the separation of the technical and professional components of Medicare billing practices. The decision notes that the relator's (Smith's) argument would disqualify YNHH from being paid for services it had rendered “if the physician's request or intended use of the study, deemed before the fact to be medically necessary, was found after the fact to be medically unreasonable and/or unnecessary.”

Other passages include that the relator “has failed to establish … subject matter jurisdiction over his claims” and “has not demonstrated that he is an original source of the facts on which his claims are based.”

Also in the text are the passages, “the allegations … are fraught with assumptions and conclusions which do not suffice to establish the essential facts” of a whistleblower claim, “and are devoid of the facts necessary to support such a claim.”

The decision also says that what the relator “alleges to be his observations are not shown to be within his personal experience,” and that his claims do not reflect “first-hand knowledge” or “direct, independent knowledge.”

As they say in the movies, capisce?

As my wife will tell you, I'm sort of inclined to crack wise at a lot of fuss and bother and can be heard asking from time to time, “what's so mellow about melodrama?” So maybe I'm the wrong person to blog about all this. But still, the only question I have about this latest Smith-based dust-up is …

What's Peyton Manning going to do?

You must login or register in order to post a comment.

Report Abusive Comment

Popular Stories

  • Free access to BioWorld coronavirus articles

    BioWorld

    The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus outbreak. Note that we have added three critical tables which are...

  • Today's news in brief

    BioWorld
    BioWorld briefs for March 2.
  • Gloved hand places sample tubes in PCR system

    COVID-19 test makers are adapting for variants

    BioWorld MedTech
    As COVID-19 variants have emerged, so have questions about the effectiveness of tests for infection. While the risk of mutations significantly limiting their...
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech's briefs for March 2.
  • Celltrion-Regkirona-2-9

    Celltrion wins first conditional Korean approval for COVID-19 antibody Regkirona

    BioWorld
    HONG KONG – Celltrion Inc. has received conditional marketing authorization from the Ministry of Food and Drug Safety (MFDS) for its anti-COVID-19 monoclonal...
cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • About
    • Archives
    • Today's news
    • Search BioWorld Science
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
A Clarivate Analytic solution. Link to Clarivate website.
Follow Us

Copyright ©2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing